Schizophrenia is a severe, persistent mental disorder, and a leading cause of disability worldwide. Cognitive impairments presented in schizophrenia lead to a worse prognostic, thus treatments targeted to enhance cognition in schizophrenia may be clinically relevant.
Aims:
The purpose of this study was to assess the efficacy of acetylcholinesterase inhibitors as add-on medication to antipsychotics on cognition in patients with schizophrenia.
Methods:
Search strategies were developed for Medline, Embase and Cochrane Central Register of Controlled Trials, and are current to March 2018. We included randomised controlled trials that compared antipsychotics plus acetylcholinesterase inhibitors versus antipsychotics plus placebo on prespecified cognitive domains (speed of processing, attention and working memory). Two review authors independently evaluated study eligibility, extracted data and assessed the risk of bias of included studies. We used random-effects model for meta-analyses and assessed the quality of evidence using Grading of Recommendations Assessment, Development and Evaluation (GRADE).
Results:
We included nine randomised controlled trials. Six randomised controlled trials (n=219) presented evidence that acetylcholinesterase inhibitors improve speed of processing (standardised mean difference −0.52, 95% confidence interval (−0.79 to −0.25); p value=0.0002). However, eight randomised controlled trials (n=252) did find placebo was better than acetylcholinesterase inhibitors in the attention domain (−0.43, (−0.72 to −0.13); p value=0.005) and eight randomised controlled trials (n=273) did not find differences in the working memory (−0.14, (−0.51 to 0.24), p value=0.47).
Conclusions:
The current evidence is too weak to base recommendations on the use of acetylcholinesterase inhibitors as adjunctive treatments to antipsychotics to improve basic cognitive functions. We have limited confidence in the effect estimates.
AkhondzadehSGeramiMNoroozianMet al. (2008) A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry32: 1810–1815.
2.
American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (DSM-5). 5th ed.Arlington, VA: American Psychiatric Publishing.
3.
BakkourNSampJAkhrasKet al. (2014) Systematic review of appropriate cognitive assessment instruments used in clinical trials of schizophrenia, major depressive disorder and bipolar disorder. Psychiatry Res216: 291–302.
BuchananRWConleyRRDickinsonDet al. (2008) Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry165: 82–89.
6.
ChoiKHWykesTKurtzMM (2013) Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: Meta-analytical investigation of efficacy. Br J Psychiatry203: 172–178.
7.
ChongHYTeohSLWuDBet al. (2016) Global economic burden of schizophrenia: A systematic review. Neuropsychiatr Dis Treat12: 357–373.
8.
ChouinardSStipEPoulinJet al. (2007) Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits. Curr Med Res Opin23: 575–583.
9.
CitromeL (2012) A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. Expert Opin Pharmacother13: 1545–1573.
10.
CohenJ (1988) Statistical Power Analysis for the Behavioral Sciences. Hillsdale: NJ: Lawrence Erlbaum Associates.
CornblattBARischNJFarisGet al. (1988) The Continuous Performance Test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families. Psychiatry Res26: 223–238.
13.
DaviesP (1985) A critical review of the role of the cholinergic system in human memory and cognition. Ann N Y Acad Sci444: 212–217.
14.
DerSimonianRLairdN (1986) Meta-analysis in clinical trials. Control Clin Trials7: 177–188.
15.
DunbarGBoeijingaPHDemazièresAet al. (2007) Effects of TC-1734 (AZD3480), a selective neuronal nicotininc receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology191: 919–929.
16.
DyerMAFreudenreichOCulhaneMAet al. (2008) High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophr Res102: 88–95.
17.
EiringOLandmarkBFAasEet al. (2015) What matters to patients? A systematic review of preferences for medication-associated outcomes in mental disorders. BMJ Open5: e007848.
18.
EricksonSKSchwarzkopfSBPalumboDet al. (2005) Efficacy and tolerability of low-dose donepezil in schizophrenia. Clin Neuropharmacol28: 179–184.
19.
FagerlundBSøholmBFink-JensenAet al. (2007) Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: A double-blind, placebo-controlled study. Clin Neuropharmacol30: 3–12.
20.
FerreriFAgbokouCGauthierS (2006) Cognitive dysfunctions in schizophrenia: Potential benefits of cholinesterase inhibitor adjunctive therapy. J Psychiatry Neurosci31: 369–376.
21.
FioravantiMBianchiVCintiME (2012) Cognitive deficits in schizophrenia: An updated metanalysis of the scientific evidence. BMC Psychiatry12: 64.
22.
FreoUPizzolatoGDamMet al. (2002) A short review of cognitive and functional neuroimaging studies of cholinergic drugs: Implications for therapeutic potentials. J Neural Transm (Vienna)109: 857–870.
23.
FreudenreichOHerzLDeckersbachTet al. (2005) Added donepezil for stable schizophrenia: A double blind, placebo-controlled trial. Psychopharmacology (Berl)181: 358–363.
24.
FriedmanJI (2004) Cholinergic targets for cognitive enhancement in schizophrenia: Focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology174: 45–53.
25.
FriedmanJIAdlerDNHowanitzEet al. (2002) A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry51: 349–357.
26.
Fusar-PoliPPapanastasiouEStahlDet al. (2015) Treatments of negative symptoms in schizophrenia: Meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull41: 892–899.
27.
GoffDCHillMBarchD (2011) The treatment of cognitive impairment in schizophrenia. Pharmacol Biochem Behav99: 245–253.
28.
GoldJMCarpenterCRandolphCet al. (1997) Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry54: 159–165.
29.
HahnEVollathATaTTMet al. (2014) Assessing long-term test-retest reliability of the CPT-IP in schizophrenia. PLoS One9: e84780.
30.
HarveyPD (2009) Pharmacological cognitive enhancement in schizophrenia. Neuropsychol Rev19: 324–335.
31.
HigginsJPThompsonSGSpiegelhalterDJ (2009) A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc172: 137–159.
32.
HigginsJPTGreenS (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. London: The Cochrane Collaboration.
HigginsJPTThompsonSGDeeksJJet al. (2003) Measuring inconsistency in meta-analyses. Br Med J327: 557–560.
35.
IntHoutJIoannidisJPRoversMMet al. (2016) Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open6: e010247.
36.
JääskeläinenEJuolaPHirvonenNet al. (2013) A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull39: 1296–1306.
37.
JablenskyA (2000) Epidemiology of schizophrenia: The global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci250: 274–285.
38.
KeefeRSEMalhotraAKMeltzerHYet al. (2008) Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: Significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology33: 1217–1228.
39.
KishiTMatsudaYIwataN (2017) Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: A meta-analysis. Psychopharmacology (Berl)234: 2113–2125.
40.
KohlerCGMartinEAKujawskiEet al. (2007) No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia. Cogn Neuropsychiatry12: 412–421.
41.
KumarPNSMohemmedaliSPAnishPKet al. (2017) Cognitive effects with rivastigmine augmentation of risperidone: A 12-month, randomized, double-blind, placebo-controlled study in schizophrenia. Indian J Psychiatry59: 219–224.
42.
LaneHYLinCHGreenMFet al. (2013) Add-on treatment of benzoate for schizophrenia: A randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry70: 1267–1275.
43.
LeeBJLeeJGKimYH (2007) A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. J Psychopharmacol21: 421–427.
44.
LeeSWKimYH (2005) A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Clin Psychopharmacol Neurosci3: 10–15.
45.
LepageMBodnarMBowieCR (2014) Neurocognition: Clinical and functional outcomes in schizophrenia. Can J Psychiatry59: 5–12.
46.
LezakMDHowiesonDBBiglerEDet al. (2012) Neuropsychological Assessment. New York: Oxford University Press.
47.
LinCYLiangSYChangYCet al. (2017) Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial. World J Biol Psychiatry18: 357–368.
48.
LindenmayerJPKhanA (2011) Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. Schizophr Res125: 267–277.
49.
MoherDLiberatiATetzlaffJet al. (2000) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med6: e1000097.
50.
OlincyAHarrisJGJohnsonLLet al. (2006) Proof-of-concept trial of an α7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry63: 630–638.
51.
R Core Team (2017) R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.
52.
ReichenbergACaspiAHarringtonHLet al. (2010) Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: A 30-year study. Am J Psychiatry167: 160–169.
53.
RibeizSRIBassittDPArraisJAet al. (2010) Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder. A review and meta-analysis of the literature. CNS Drugs24: 303–317.
54.
RyanABakerADarkFet al. (2017) The efficacy of sodium benzoate as an adjunctive treatment in early psychosis - CADENCE-BZ: Study protocol for a randomized controlled trial. Trials18: 165.
55.
Sánchez-CubilloIPeriáñezJAAdrover-RoigDet al. (2009) Construct validity of the Trail Making Test: Role of task-switching, working memory, inhibition/interference control, and visuomotor abilities. J Int Neuropsychol Soc15: 438–450.
56.
SchubertMHYoungKAHicksPB (2006) Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol Psychiatry60: 530–533.
57.
SchünemannHBrozekJGuyattGet al. (2013) GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. The GRADE Working Group. Available at: http://www.who.int/hiv/topics/mtct/grade_handbook.pdf (accessed 28 September 2018)
58.
SchwarzerG (2007) meta: An R package for meta-analysis. R News7: 40–45.
59.
SharmaTReedCAasenIet al. (2006) Cognitive effects of adjunctive 24-weeks rivastigmine treatment to antipsychotics in schizophrenia: A randomized, placebo-controlled, double-blind investigation. Schizophr Res85: 73–83.
StipESepehryAAChouinardS (2007) Add-on therapy with acetylcholinesterase inhibitors for memory dysfunction in schizophrenia: A systematic quantitative review, part 2. Clin Neuropharmacol30: 218–228.
62.
StryjerRStrousRBarFet al. (2004) Donepezil augmentation of clozapine monotherapy in schizophrenia patients: A double blind cross-over study. Hum Psychopharmacol19: 343–346.
63.
The Nordic Cochrane Centre and The Cochrane Collaboration (2012) Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration.
64.
TuğalÖYaziciKMYağcioğluAEAet al. (2004) A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int J Neuropsychopharmacol7: 117–123.
65.
VelliganDBrennerRSicuroFet al. (2012) Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia. Schizophr Res134: 59–64.
66.
ViechtbauerW (2010) Conducting meta-analyses in R with the metafor package. J Stat Softw36: 1–48.
67.
WechslerD (1981) Wechsler Adult Intelligence Scaled-Revised Manual. San Antonio: TX: The Psychological Corporation.
68.
WhitefordHAFerrariAJDegenhardtLet al. (2015) The global burden of mental, neurological and substance use disorders: An analysis from the Global Burden of Disease Study 2010. PLoS One10: e0116820.
69.
ZabalaARapadoMArangoCet al. (2010) Neuropsychological functioning in early-onset first-episode psychosis: Comparison of diagnostic subgroups. Eur Arch Psychiatry Clin Neurosci260: 225–233.
70.
ZhuWZhangZQiJet al. (2014) Adjunctive treatment for cognitive impairment in patients with chronic schizophrenia: A double-blind, placebo-controlled study. Neuropsychiatr Dis Treat10: 1317–1323.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
